U.S. pharma giant copyright scrapped two experimental weight loss products last year—a the moment-day-to-day pill, lotiglipron, as a consequence of elevated liver enzymes and also a twice-each day tablet, danuglipron, due to solid Unwanted effects—but CEO Albert Bourla has reported the company is decided to “play and acquire” while in the o